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www.jacc-interventions.org to view.“Virtual” (Computed) Fractional Flow Reserve: Current Challenges and Limitations 1009
Paul D. Morris, Frans N. van de Vosse, Patricia V. Lawford, D. Rodney Hose, Julian P. GunnPercutaneous coronary intervention (PCI) guided by fractional ﬂow reserve (FFR) improves clinical
outcomes and reduces stent insertion and cost. However, <10% of PCI cases beneﬁt from FFR
measurement due to procedure- and operator-related factors. Computed virtual fractional ﬂow
reserve (vFFR) offers the advantages of physiological coronary lesion assessment without the
factors limiting use of the invasive technique. Herein, the key clinical, methodological, commercial,
logistic, and political challenges that vFFR must overcome are explored. Assuming successful
development continues in these key areas, vFFR is likely to become a desirable tool in the
functional assessment of coronary artery disease.CLINICAL RESEARCH
CORONARY Repeatability of Fractional Flow Reserve Despite Variations in Systemic and
Coronary Hemodynamics1018Nils P. Johnson, Daniel T. Johnson, Richard L. Kirkeeide, Colin Berry, Bernard De Bruyne,
William F. Fearon, Keith G. Oldroyd, Nico H.J. Pijls, K. Lance GouldAlthough fractional ﬂow reserve (FFR) has become a key invasive tool to guide treatment, questions
remain regarding its repeatability and stability during intravenous adenosine infusion because of
systemic effects that can alter the hemodynamics. The authors reanalyzed 190 paired FFR tracings
from the VERIFY (VERiﬁcation of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for
the Assessment of Coronary Artery Stenosis Severity in EverydaY Practice) study using a novel
“smart minimum” algorithm. Visual analysis revealed 3 FFR response patterns: “classic” (sigmoid) in
57%, “humped” (sigmoid with superimposed bumps of varying height) in 39%, and “unusual”
(no pattern) in 4%. Despite hemodynamic variability during hyperemia, the “smart minimum” FFR
demonstrated excellent repeatability. Therefore, operators can conﬁdently select this FFR for
patient care.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Selecting the Right Fractional Flow Reserve in an Unsteady State: Keep It Simple 1028
Morton J. Kern, Arnold H. SetoCONTINUED ON PAGE A-23
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JULY 2015 VOLUME 8, NUMBER 8Outcomes of Comatose Cardiac Arrest Survivors With and Without ST-Segment
Elevation Myocardial Infarction: Importance of Coronary Angiography1031Karl B. Kern, Kapildeo Lotun, Nainesh Patel, Michael R. Mooney, Ryan D. Hollenbeck,
John A. McPherson, Paul W. McMullan, Barbara Unger, Chiu-Hsieh Hsu, David B. Seder,
for the INTCAR-Cardiology RegistryThis study evaluated outcomes and coronary angiographic ﬁndings for those with and without
ST-segment elevation myocardial infarction (STEMI) after cardiac arrest. A culprit vessel was
found more commonly when STEMI was present but was also present in one-third of patients
without STEMI. The majority of culprit vessels were occluded. Coronary angiography in patients
without STEMI was associated with an increase in survival with good neurological function equal
to that achieved in those with STEMI undergoing immediate angiography.n EDITORIAL COMMENT
Are We There Yet? Should All Comatose Cardiac Arrest Survivors Go to the Cath Lab? 1041
R. David Anderson
Comparison of Neoatherosclerosis and Neovascularization Between Patients With and
Without Diabetes: An Optical Coherence Tomography Study1044Lei Gao, Seung-Jung Park, Yangsoo Jang, Stephen Lee, Chong-Jin Kim,
Yoshiyasu Minami, Daniel Ong, Tsunenari Soeda, Rocco Vergallo, Hang Lee,
Bo Yu, Shiro Uemura, Ik-Kyung JangIn vivo neoatherosclerosis (NA) characteristics in patients with diabetes mellitus (DM) have not been
systematically studied. The authors investigated NA characteristics in 397 patients who underwent
follow-up optical coherence tomography examination more than 6 months after drug-eluting
stent implantation. Although the incidence of NA was similar, NA lesions in DM patients had a
higher prevalence of neovascularization. Moreover, poorly controlled DM patients had a higher
prevalence of thin-cap ﬁbroatheroma.
Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in
Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting
Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent1053Yuki Ishibashi, Takashi Muramatsu, Shimpei Nakatani, Yohei Sotomi,
Pannipa Suwannasom, Maik J. Grundeken, Yun-kyeong Cho, Hector M. Garcia-Garcia,
Ad J. van Boven, Jan J. Piek, Manel Sabaté, Steffen Helqvist, Andreas Baumbach,
Dougal McClean, Manuel de Sousa Almeida, Luc Wasungu, Karine Miquel-Hebert,
Dariusz Dudek, Bernard Chevalier, Yoshinobu Onuma, Patrick W. SerruysThis study sought to evaluate the mechanism of post-procedural cardiac biomarker (CB) rise
following device implantation. A fully bioresorbable Absorb scaffold, compared with everolimus-
eluting metallic stents, might be associated with a higher incidence of periprocedural myocardial
injury. Incidence of side branch occlusion and any anatomic complications assessed by angiography
was similar between the 2 treatment arms. Treatment with overlapping devices was the only
independent determinant of per-protocol periprocedural myocardial infarction. There were no
differences in the incidence of CB rise and periprocedural myocardial infarction between Absorb
and everolimus-eluting metallic stents.
SEE ADDITIONAL CONTENT ONLINECONTINUED ON PAGE A-24
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JULY 2015 VOLUME 8, NUMBER 8Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the
Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized
Observational Study1064Lorenz Räber, Roland Klingenberg, Dik Heg, Henning Kelbæk, Marco Rofﬁ, David Tüller,
Andreas Baumbach, Thomas Zanchin, David Carballo, Miodrag Ostojic,
Giulio G. Stefanini, Nicolas Rodondi, Clemens von Birgelen, Aris Moschovitis,
Thomas Engstrøm, Baris Gencer, Reto Auer, Bernhard Meier, Francois Mach,
Thomas F. Lüscher, Peter Jüni, Christian M. Matter, Stephan Windecker,
for the COMFORTABLE and SPUM-ACS Trial InvestigatorsThe authors assessed the safety of a prasugrel loading dose in patients undergoing primary
percutaneous coronary intervention in the setting of ST-segment elevation myocardial infarction.
Patients receiving a prasugrel loading dose were divided into those receiving clopidogrel and a
subsequent prasugrel loading dose or a prasugrel loading dose only. Bleeding Academic Research
Consortium types 3 to 5 bleeding was assessed at 30 days. A total of 427 patients received
clopidogrel and a subsequent prasugrel loading dose and 447 received a prasugrel loading dose
alone. There were no differences in the primary safety endpoint of Bleeding Academic Research
Consortium types 3 to 5 bleeding at 30 days (adjusted hazard ratio [clopidogrel and a subsequent
prasugrel loading dose vs. a prasugrel loading dose alone]: 0.57; 95% conﬁdence interval: 0.25 to
1.30), suggesting that that a loading dose of prasugrel in patients pre-treated with clopidogrel is
not associated with an excess of major bleeding.
SEE ADDITIONAL CONTENT ONLINEPharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance
Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind
Investigation1075Jung Rae Cho, Fabiana Rollini, Francesco Franchi, Christopher DeGroat, Mona Bhatti,
Elizabeth C. Dunn, Elisabetta Ferrante, Ana Muniz-Lozano, Siva Suryadevara,
Martin M. Zenni, Luis A. Guzman, Theodore A. Bass, Dominick J. AngiolilloTo date, investigations assessing dosing regimens of P2Y12 receptor inhibitors in patients
on maintenance therapy have been only assessed with thienopyridines, but not with ticagrelor.
This was a prospective, randomized, double-blind, placebo-controlled study assessing the
pharmacodynamics effects of 2 dosing regimens of ticagrelor (90 mg vs. 180 mg) in patients on
standard aspirin and ticagrelor maintenance therapy (N ¼ 60). The study showed that compared
with a 90-mg dose, a 180-mg reloading dose of ticagrelor is associated with enhanced platelet
inhibition in patients on maintenance therapy. Furthermore, enhanced platelet inhibitory effects
were achieved promptly with this regimen.
SEE ADDITIONAL CONTENT ONLINECONTINUED ON PAGE A-25
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JULY 2015 VOLUME 8, NUMBER 8STRUCTURAL 5-Year Outcomes After Transcatheter Aortic Valve Implantation With
CoreValve Prosthesis1084Marco Barbanti, Anna Sonia Petronio, Federica Ettori, Azeem Latib, Francesco Bedogni,
Federico De Marco, Arnaldo Poli, Carla Boschetti, Marco De Carlo, Claudia Fiorina,
Antonio Colombo, Nedy Brambilla, Giuseppe Bruschi, Paola Martina, Claudia Pandolﬁ,
Cristina Giannini, Salvatore Curello, Carmelo Sgroi, Simona Gulino, Martina Patanè,
Yohei Ohno, Claudia Tamburino, Guilherme F. Attizzani, Sebastiano Immè,
Alessandra Gentili, Corrado TamburinoThe objective of this analysis from the ClinicalService Project was to assess 5-year outcomes of
transcatheter aortic valve implantation (TAVI) using the current technology of self-expanding
CoreValve prosthesis (Medtronic Inc., Minneapolis, Minnesota). Barbanti et al. found that TAVI
with the currently adopted CoreValve generation was associated with sustained clinical outcomes
up to 5-year follow-up, with a low rate (1.4%) of signiﬁcant prosthetic valve degeneration. The
procedure appears to be an adequate and lasting resolution of aortic stenosis in selected high-risk
patients.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Is Transcatheter Aortic Valve Replacement a Durable Therapeutic Strategy? 1092
John G. Webb, Danny Dvir
Treatment of Heart Failure With Associated Functional Mitral Regurgitation Using the
ARTO System: Initial Results of the First-in-Human MAVERIC Trial (Mitral Valve
Repair Clinical Trial)1095Jason H. Rogers, Martyn Thomas, Marie-Claude Morice, Inga Narbute, Milana Zabunova,
Thomas Hovasse, Mathieu Poupineau, Ainars Rudzitis, Ginta Kamzola, Ligita Zvaigzne,
Samantha Greene, Andrejs ErglisThe ARTO system percutaneously modiﬁes the mitral annulus to improve leaﬂet coaptation in
patients with functional mitral regurgitation (FMR). The MAVERIC (Mitral Valve Repair Clinical
Trial) is a prospective, nonrandomized ﬁrst-in-human study using the ARTO system to treat
patients with symptomatic heart failure and FMR. Eleven patients were treated with the ARTO
system, resulting in meaningful reductions in FMR grade and improvement in New York Heart
Association functional class at 30 days. There were 2 adverse events: 1 pericardial effusion
requiring surgical drainage, and 1 asymptomatic device dislodgement. The ARTO system is
effective in the treatment of FMR complicating systolic heart failure.CONTINUED ON PAGE A-26
CONTENTS
PAGE A-26
JULY 2015 VOLUME 8, NUMBER 8PERIPHERAL 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and
Proximal Popliteal Artery): Predictors of Restenosis1105Osamu Iida, Mitsuyoshi Takahara, Yoshimitsu Soga, Masatsugu Nakano,
Yasutaka Yamauchi, Kan Zen, Daizo Kawasaki, Shinsuke Nanto, Hiroyoshi Yokoi,
Masaaki Uematsu, on behalf of the ZEPHYR InvestigatorsThe current study demonstrated 1-year real-world outcomes after drug-eluting stent implantation
for femoropopliteal lesions. Lesion length, distal external elastic membrane area, and minimum
stent area were independent predictors for restenosis.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
What’s a Doctor to Do? Balloon, Stents, Drugs, Drills, and Treadmills:
Are We Closer to the Optimal Algorithm?1113Michael R. JaffTRANSLATIONAL Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing:
A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic
Swine Model of Superﬁcial Femoral In-Stent Restenosis1115Carlos A. Gongora, Masahiko Shibuya, Jeffrey D. Wessler, Jenn McGregor,
Armando Tellez, Yanping Cheng, Gerard B. Conditt, Greg L. Kaluza, Juan F. GranadaThe optimal therapeutic dose for paclitaxel-coated balloon (PCB) use has not been determined yet.
This study sought to compare the effect of PCB concentration on tissue levels and vascular healing
using 2 different PCB concentrations (3 mg/mm2 vs. 2 mg/mm2) in the experimental setting.
Lower-dose PCB technologies achieved lower long-term tissue levels but comparable degrees of
neointimal inhibition and fewer peri-strut ﬁbrin deposits than did the clinically established PCB
dose. The impact of these ﬁndings in restenosis reduction and clinical outcomes needs to be
further investigated.IMAGES IN
INTERVENTIONIatrogenic Aortocoronary Arteriovenous Fistula: Percutaneous Management of a
Surgical Complication1124Zaher Fanari, Jhapat Thapa, Armin Barekatain, Kevin Copeland, James T. Hopkins
Tricuspid Valve Replacement: A Percutaneous Transfemoral Valve-in-Ring Approach 1126
Alduz S. Cabasa, Mackram F. Eleid, Charanjit S. Rihal, Hector R. Villarraga,
Thomas A. Foley, Rakesh M. SuriCONTINUED ON PAGE A-27
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JULY 2015 VOLUME 8, NUMBER 8n ONLINE FEATURE Instant Stent-Accentuated 3-Dimensional Optical Coherence
Tomography of Struts Pulled Up by Pulling Stuck Wire and Folded by
Kissing Balloon Dilatione125Fumiaki Nakao
n ONLINE FEATURE Drug-Eluting Stent Implantation on Calciﬁed Nodule:
Ex Vivo Intravascular Images and Histopathologye127Rika Kawakami, Hiroyuki Hao, Yaemi Takagi, Akiko Fujino, Yasu-aki Tsuchida,
Takahiro Imanaka, Kenichi Fujii, Seiichi Hirota
n ONLINE FEATURE Percutaneous Transcatheter Closure for Aortic Puncture and
Paravalvular Leak Closure With the New Amplatzer III Devicee129Bernhard Meier, Bernhard Winkler, Thierry Carrel, Christoph Huber
n ONLINE FEATURE A Patient With Kawasaki’s Disease and Increasing
Breathlessnesse131Hani Abdel-Hadi, Ashish H. Shah, Robert J. Cusimano, Christopher Overgaard
n ONLINE FEATURE 5-Year Follow-Up After Stenting for Iatrogenic Coronary
Stenosis Due to Mitral Annuloplasty: Insights With Multiple Imaging Modalitiese133Satoru Mitomo, Toru Naganuma, Koji Hozawa, Kensuke Takagi, Tatsuya Nakao,
Sunao Nakamura
n ONLINE FEATURE Excimer Laser Angioplasty–Facilitated Fracturing of Napkin-Ring
Peri-Stent Calcium in a Chronically Underexpanded Stent: Documentation by
Optical Coherence Tomographye137Da Yin, Akiko Maehara, Stephen Mezzafonte, Jeffrey W. Moses, Gary S. Mintz,
Richard A. Shlofmitz
n ONLINE FEATURE THESE ARTICLES DO NOT APPEAR IN THE PRINTED ISSUE.
THEY ARE AVAILABLE IN THE ONLINE VERSION OF THIS ISSUE.LETTERS TO
THE EDITORCoronary Occlusion and Ischemia Reduction 1129
C. Richard Conti
Reply
Woo Jin Jang, Jeong Hoon Yang, Seung-Hyuk Choi, Young Bin Song, Joo-Yong Hahn,
Jin-Ho Choi, Wook Sung Kim, Young Tak Lee, Hyeon-Cheol Gwon
Fate of Bioresorbable Vascular Scaffold Metallic Radio-Opaque Markers at the
Site of Implantation After Bioresorption1130Pannipa Suwannasom, Yoshinobu Onuma, Carlos M. Campos, Shimpei Nakatani,
Yuki Ishibashi, Hiroki Tateishi, Maik J. Grundeken, Bojan Stanetic, Koen Nieman,
Hans Jonker, Hector M. Garcia-Garcia, Patrick W. Serruys, on behalf of the investigators
of ABSORB Cohort A, B and EXTEND trialsSEE ADDITIONAL CONTENT ONLINECONTINUED ON PAGE A-28
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JULY 2015 VOLUME 8, NUMBER 83-Year Follow-Up of the Balloon Elution and Late Loss Optimization Study (BELLO) 1132
Azeem Latib, Neil Ruparelia, Alberto Menozzi, Fausto Castriota, Antonio Micari,
Alberto Cremonesi, Francesco De Felice, Alfredo Marchese, Maurizio Tespili,
Patrizia Presbitero, Gregory A. Sgueglia, Francesca Buffoli, Corrado Tamburino,
Ferdinando Varbella, Antonio Colombo
Risk Adjusted Mortality Ratings and Public Reporting for High-Risk PCI 1134
Matthew W. Sherwood, Eric D. Peterson
Uncertain Detection of Nonuniform Scaffold Expansion Patterns Using
Optical Coherence Tomography1135Lene Nyhus Andreasen, Ida Riise Balleby, Niels Ramsing Holm
Reply
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